
Apr 8, 2025, 06:07
Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers
Margherita Ambrosini, Medical Oncologist at National Cancer Institute of Milan IRCCS Foundation, shared a post on LinkedIn:
“In this review, we delve into the key features of MSI-H/dMMR cancers, shedding light on current diagnostic challenges and the impact of immune checkpoint inhibitors across both advanced and early-stage disease.
Have a look!”
Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers
Authors: Margherita Ambrosini, Paolo Manca, Vincenzo Nasca, Carolina Sciortino, Filippo Ghelardi, Jenny F. Seligmann, Julien Taieb and Filippo Pietrantonio.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 15, 2025, 18:57
Apr 15, 2025, 18:26
Apr 15, 2025, 17:49
Apr 15, 2025, 17:41